CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2015 to Q4 2025

Type / Class
Equity / Common Stock, $0.00001 par value per share
Symbol
CTMX on Nasdaq
Shares outstanding
165,547,872
Price per share
$4.26
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
137,411,371
Total reported value
$438,342,190
% of total 13F portfolios
0%
Share change
+4,106,262
Value change
+$24,527,201
Number of holders
102
Price from insider filings
$4.26
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 12% +34% $65,458,695 +$16,344,817 20,519,967 +33% FMR LLC 31 Oct 2025
Venrock Healthcare Capital Partners III, L.P. 9.4% +15% $49,641,185 +$8,195,110 15,561,500 +20% Venrock Healthcare Capital Partners III, L.P. 30 Sep 2025
Longitude Capital Partners V, LLC 7.3% $8,192,307 11,538,461 Longitude Capital Partners V, LLC 13 May 2025
TANG CAPITAL MANAGEMENT LLC 7% -18% $22,131,324 +$8,695,674 11,065,662 +65% TANG CAPITAL MANAGEMENT, LLC 30 Jun 2025
PERCEPTIVE ADVISORS LLC 5.9% $19,360,370 9,680,185 Perceptive Advisors LLC 14 Aug 2025
VANGUARD GROUP INC 6% $23,449,485 9,379,794 The Vanguard Group 30 Jun 2025
ORBIMED ADVISORS LLC 5.4% $16,923,000 8,461,500 OrbiMed Advisors LLC 30 Jun 2025
BIOTECHNOLOGY VALUE FUND L P 3.5% -47% $14,423,078 -$14,423,078 5,769,231 -50% BVF PARTNERS L P/IL 03 Jul 2025
Point72 Asset Management, L.P. 2.5% -52% $12,978,754 -$12,811,193 4,068,575 -50% Point72 Asset Management, L.P. 30 Sep 2025
Seven Fleet Partners LP 0.2% $267,784 377,161 Seven Fleet Partners LP 13 May 2025
Seven Fleet Capital Management LP 0.02% $155,985 48,898 Seven Fleet Master Fund LP 30 Sep 2025

As of 30 Sep 2025, 102 institutional investors reported holding 137,411,371 shares of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX). This represents 83% of the company’s total 165,547,872 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) together control 75% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VR ADVISER, LLC 9.4% 15,561,500 +11% 2.8% $49,641,185
FMR LLC 9.3% 15,396,200 +67% 0% $49,113,878
TANG CAPITAL MANAGEMENT LLC 6.7% 11,065,662 0% 1.4% $35,299,462
PERCEPTIVE ADVISORS LLC 5.8% 9,680,185 +38% 0.9% $30,879,790
VANGUARD GROUP INC 5.4% 8,947,807 -4.6% 0% $28,543,505
ORBIMED ADVISORS LLC 5.1% 8,461,500 0% 0.65% $26,992,185
Commodore Capital LP 4.6% 7,692,300 0% 1.2% $24,538,437
BAKER BROS. ADVISORS LP 2.6% 4,250,826 +22% 0.1% $13,560,135
Point72 Asset Management, L.P. 2.5% 4,068,575 -50% 0.03% $12,978,754
ADAR1 Capital Management, LLC 2.4% 4,045,414 +31% 1.3% $12,904,871
Balyasny Asset Management L.P. 2.4% 3,913,081 +37% 0.03% $12,482,728
Kynam Capital Management, LP 2.2% 3,646,503 +69% 0.87% $11,632,345
RTW INVESTMENTS, LP 2.1% 3,461,500 0% 0.14% $11,042,185
Ikarian Capital, LLC 2% 3,372,616 2.4% $10,758,645
Vivo Capital, LLC 1.7% 2,884,615 -50% 0.74% $9,201,922
RA CAPITAL MANAGEMENT, L.P. 1.6% 2,661,331 0% 0.1% $8,489,646
RENAISSANCE TECHNOLOGIES LLC 1.5% 2,545,260 +37% 0.01% $8,119,379
BlackRock, Inc. 1.4% 2,381,912 -0.27% 0% $7,598,299
Woodline Partners LP 1.4% 2,337,005 +0% 0.04% $7,455,046
CITADEL ADVISORS LLC 1.1% 1,800,435 +2006% 0% $5,743,387
GEODE CAPITAL MANAGEMENT, LLC 0.95% 1,569,298 -10% 0% $5,008,010
MILLENNIUM MANAGEMENT LLC 0.84% 1,386,863 +494% 0% $4,424,093
Financial Engines Advisors L.L.C. 0.83% 1,381,357 0.01% $4,406,529
BOOTHBAY FUND MANAGEMENT, LLC 0.75% 1,237,057 0.1% $3,946,212
MARSHALL WACE, LLP 0.67% 1,104,993 -53% 0% $3,524,928

Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 750,490 $3,196,843 -$859,639 $4.26 4
2025 Q3 137,411,371 $438,342,190 +$24,527,201 $3.19 102
2025 Q2 133,305,109 $302,602,132 +$213,796,965 $2.27 82
2025 Q1 45,180,958 $28,723,084 -$1,507,776 $0.64 63
2024 Q4 46,714,805 $48,111,898 -$6,381,441 $1.03 68
2024 Q3 51,193,741 $60,427,306 +$480,726 $1.18 70
2024 Q2 50,687,257 $61,863,474 +$881,574 $1.22 73
2024 Q1 44,549,526 $97,120,414 +$24,340,988 $2.18 86
2023 Q4 31,503,242 $48,830,902 +$391,970 $1.55 64
2023 Q3 31,253,678 $40,315,675 -$2,408,012 $1.29 60
2023 Q2 34,119,916 $58,687,106 -$2,378,084 $1.72 65
2023 Q1 34,470,061 $52,048,591 -$652,178 $1.51 72
2022 Q4 34,595,835 $55,359,376 -$51,520 $1.60 75
2022 Q3 36,262,081 $52,574,898 -$18,715,674 $1.45 74
2022 Q2 45,243,734 $82,728,420 -$18,503,049 $1.83 85
2022 Q1 53,657,441 $143,345,949 -$1,362,213 $2.67 111
2021 Q4 54,245,198 $234,877,521 -$5,208,112 $4.33 104
2021 Q3 53,860,171 $274,182,521 -$13,037,256 $5.09 110
2021 Q2 55,789,405 $353,148,555 -$140,688 $6.33 115
2021 Q1 54,567,681 $421,799,729 +$130,729,085 $7.73 124
2020 Q4 37,916,172 $248,362,255 +$6,766,812 $6.55 122
2020 Q3 36,833,470 $245,018,950 -$11,496,756 $6.65 127
2020 Q2 37,729,759 $314,277,192 +$28,164,183 $8.33 130
2020 Q1 36,053,150 $276,613,388 +$523,283 $7.67 110
2019 Q4 35,742,896 $297,010,261 -$9,661,954 $8.31 116
2019 Q3 35,811,948 $264,247,175 +$883,687 $7.38 110
2019 Q2 35,647,194 $399,598,509 -$8,080,331 $11.22 108
2019 Q1 36,654,668 $394,020,592 -$12,842,306 $10.75 105
2018 Q4 37,549,904 $566,582,178 +$45,687 $15.10 104
2018 Q3 37,698,109 $697,358,587 +$95,615,701 $18.50 117
2018 Q2 32,089,285 $733,618,935 +$67,025,711 $22.86 137
2018 Q1 28,567,397 $812,623,475 +$71,804,541 $28.45 134
2017 Q4 30,025,605 $634,386,631 +$55,521,976 $21.11 118
2017 Q3 24,242,512 $440,733,363 +$43,027,675 $18.17 97
2017 Q2 22,096,486 $342,576,825 +$44,947,475 $15.50 87
2017 Q1 19,203,716 $330,795,943 +$57,723,144 $17.27 85
2016 Q4 16,857,707 $185,279,386 +$14,954,366 $10.99 68
2016 Q3 15,480,759 $242,692,929 +$18,073,157 $15.68 60
2016 Q2 14,586,209 $148,983,725 +$15,967,360 $10.21 56
2016 Q1 12,753,430 $164,488,000 +$3,314,619 $12.90 45
2015 Q4 12,467,444 $258,222,359 +$239,880,349 $20.87 46